Contents:
In the next year, analysts predict that Fair Value will reach $3.58 – an increase of 100.00%. For the next nine years, the forecast is for Fair Value to grow by 100.00%. The average analyst rating for ViewRay stock from 14 stock analysts is “Buy”. This means that analysts believe this stock is likely to outperform the market over the next twelve months. ViewRay, Inc. designs, manufactures, and markets the MRIdian MRI-guided Radiation Therapy System.
This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies. The https://day-trading.info/ company’s average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings. Zacks provides the average brokerage recommendation for thousands of stocks for most of the leading investment web sties.
Please do not rely on them blindly; instead, use them as one tool in your decision-making process. Analyst ratings can change quickly, and a rating that was accurate six months ago might not be relevant today. Analyst ratings are recommendations made by various stock analysts. Public companies are rated by analysts who monitor their industries. These stock ratings result from a thorough evaluation of a traded company using known metrics such as sales, earnings, and potential catalysts.
ViewRay’s EPS has decreased In the last two years, from $-1.12 to $-0.67 – a 40.18% drop. In the next year, analysts predict that EPS will reach $-0.83 – an increase of 23.78%. For the next nine years, the forecast is for EPS to grow by 25.08%.
Top Fintech Company
The average price target for ViewRay is $6.25 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $4.00. This represents a potential 76.55% upside from VRAY’s last price of $3.54. In a report released today, Marie Thibault from BTIG reiterated a Buy rating on Viewray (VRAY – Research Report), with a price target of $7.00. The company’s shares closed yesterday at $4.45.According to TipRanks, Thibault… The best way to use analyst ratings is to supplement your investment research.
A staggering $226 BILLION is earmarked for projects requiring huge amounts of copper. Turns out, copper is a desperately needed mineral to power the green revolution of clean, renewable energy. Earnings for ViewRay are expected to grow in the coming year, from ($0.60) to ($0.49) per share. MarketBeat has tracked 6 news articles for ViewRay this week, compared to 2 articles on an average week. ViewRay does not have a long track record of dividend growth.
ViewRay (VRAY) Reports Q4 Loss, Misses Revenue Estimates
However, it can guide investors looking to buy or sell a stock. On average, Wall Street analysts predict that Viewray’s share price could reach $7.00 by Feb 28, 2024. The average Viewray stock price prediction forecasts a potential upside of 97.74% from the current VRAY share price of $3.54. StockForecast enables investors to make better investment decisions by providing financial data and objective market analysis. StockForecast has the objective information you need to analyze stocks and currencies. StockForecast is not a personal financial advisor and does not make recommendations or offers to buy or sell securities or currencies.
Advisory Research Inc. Has $1.61 Million Holdings in ViewRay, Inc … – MarketBeat
Advisory Research Inc. Has $1.61 Million Holdings in ViewRay, Inc ….
Posted: Wed, 15 Mar 2023 10:44:16 GMT [source]
ViewRay’s last stock rating was published by Piper Sandler on Aug 02, 2022. The company gave VRAY a “Overweight” rating, the same as its previous rate. The 8 analysts offering 1 year price forecasts for VRAY have a max estimate of — and a min estimate of —. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. High institutional ownership can be a signal of strong market trust in this company.
Analyst’s Opinion
In the past three months, ViewRay insiders have not sold or bought any company stock. Only 4 people have searched for VRAY on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
ViewRay’s average quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VRAY’s average quarter net income forecast represents a NaN% decrease compared to the company’s last quarter net income of $NaN . ViewRay’s average annual net income forecast for undefined is $NaN, with a range of $NaN to $NaN.
View analysts price targets for VRAY or view top-rated stocks among Wall Street analysts. 5 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for ViewRay in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” VRAY shares.
Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. 5 employees have rated ViewRay Chief Executive Officer Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among the company’s employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
In the next year, analysts expect Free Cash Flow to reach $-72.36M – an increase of 13.68%. For the next nine years, the forecast is for Free Cash Flow to grow by 13.79%. ViewRay’s Price has grown in the last two years, jumping from $0.00 to $0.00 – an increase of 100.00%.
In 2022, ViewRay’s revenue was $102.21 million, an increase of 45.76% compared to the previous year’s $70.12 million. There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viewray (VRAY – Research Report) and IN8bio (INAB – Research Report) with bullish sentiments. With a 7.85% short float and 5.25 days to cover I would expect a large spike in the next few days to finish off this pattern.
SUNY Upstate Cancer Center Chooses ViewRay’s MRI-Guided Radiation Therapy System to Treat Cancer Patients
Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Based on short-term price targets offered by seven analysts, the average price target for ViewRay comes to $7.14. The average price target represents an increase of 101.69% from the last closing price of $3.54. A price target is a stock market term used by investors and analysts to indicate the level at which they believe a stock will trade. The price target is based on several factors, including a company’s earnings, revenue, and valuation. Determining a price target can be tricky, as it is an estimate and not always accurate.
- That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
- Since then, VRAY shares have decreased by 21.0% and is now trading at $3.54.
- Please do not rely on them blindly; instead, use them as one tool in your decision-making process.
- In the next year, analysts predict that Fair Value will reach $3.58 – an increase of 100.00%.
- Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.
Over the next nine years, experts predict that EBIT will grow by 3.55%. In the last two years, ViewRay’s Net Income has gone down from $-120.20M to $-110.05M – a 8.44% drop. For next year, the 0 analysts predict Net Income of $-112.80M, which would mean 11 best online brokers for stock trading of march 2021 an increase of 2.50%. Over the next nine years, the pros’ prediction is Net Incomeof $-112.60M, which would mean a nine-year growth forecast of 2.32%. The average price target estimation represents a 76.55% change from ViewRay’s last price ($3.54).
Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist.
The ABR is the calculated average of the actual recommendations made by the brokerage firms for a given stock. ViewRay, Inc. engages in the design, manufacture and market magnetic resonance imaging system. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH. In the last two years, ViewRay’s EBIT has decreased by 8.19%, going from $-112.90M to $-103.65M. For the next year, analysts are expecting EBIT to reach $-107.46M – an increase of 3.68%.
ViewRay Announces Third Quarter 2022 Results
According to 14 analysts, the average rating for VRAY stock is “Buy.” The 12-month stock price forecast is $7.27, which is an increase of 105.95% from the latest price. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. This estimation is based on a high estimate of $10.00 and a low estimate of $7.00. Even if you are not interested in VRAY stock, you should still be aware of its competitors.